Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn R Webster

Showing results (81-90 of 131) with videos related to

Pageof 14
Sort By:
BMC Neurology|October 13, 2010
Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgiaLynn R Webster, Marvin Tark, Richard Rauck, et al.
Pain Medicine (Malden, Mass.)|June 23, 2016
Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid UsersMona Darwish, Mary Bond, Yuju Ma, et al.
Pain Medicine (Malden, Mass.)|September 22, 2016
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid UsersLynn R Webster, Michael D Smith, John Lawler, et al.
Therapeutic Advances in Drug Safety|February 13, 2019
Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled studyAlmasa Bass, Lynn R Webster, Kyle T Matschke, et al.
Current Reviews in Clinical and Experimental Pharmacology|February 26, 2021
Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory DepressionLynn R Webster, Erik Hansen, Gregory J Stoddard, et al.
Postgraduate Medicine|December 4, 2015
Opioid abuse-deterrent strategies: role of clinicians in acute pain managementLynn R Webster, Michael J Brennan, Louis M Kwong, et al.
Journal of Clinical Pharmacy and Therapeutics|July 9, 2021
Wooden Chest syndrome: The atypical pharmacology of fentanyl overdoseJoseph V Pergolizzi, Lynn R Webster, Eugene Vortsman, et al.
Pain Medicine (Malden, Mass.)|June 14, 2018
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid ClassLynn R Webster, Randall P Brewer, Peter Lichtlen, et al.
Pain Medicine (Malden, Mass.)|April 3, 2018
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent FormulationLynn R Webster, Matthew Iverson, Carmela Pantaleon, et al.
Journal of Opioid Management|January 11, 2019
A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulationNadav Friedmann, Michael R Marsman, Annelies W de Kater, et al.
Pageof 14

Showing results (81-90 of 131) with videos related to

Sort By:
Pageof 14
BMC Neurology|October 13, 2010
Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgiaLynn R Webster, Marvin Tark, Richard Rauck, et al.
Pain Medicine (Malden, Mass.)|June 23, 2016
Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid UsersMona Darwish, Mary Bond, Yuju Ma, et al.
Pain Medicine (Malden, Mass.)|September 22, 2016
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid UsersLynn R Webster, Michael D Smith, John Lawler, et al.
Therapeutic Advances in Drug Safety|February 13, 2019
Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled studyAlmasa Bass, Lynn R Webster, Kyle T Matschke, et al.
Current Reviews in Clinical and Experimental Pharmacology|February 26, 2021
Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory DepressionLynn R Webster, Erik Hansen, Gregory J Stoddard, et al.
Postgraduate Medicine|December 4, 2015
Opioid abuse-deterrent strategies: role of clinicians in acute pain managementLynn R Webster, Michael J Brennan, Louis M Kwong, et al.
Journal of Clinical Pharmacy and Therapeutics|July 9, 2021
Wooden Chest syndrome: The atypical pharmacology of fentanyl overdoseJoseph V Pergolizzi, Lynn R Webster, Eugene Vortsman, et al.
Pain Medicine (Malden, Mass.)|June 14, 2018
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid ClassLynn R Webster, Randall P Brewer, Peter Lichtlen, et al.
Pain Medicine (Malden, Mass.)|April 3, 2018
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent FormulationLynn R Webster, Matthew Iverson, Carmela Pantaleon, et al.
Journal of Opioid Management|January 11, 2019
A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulationNadav Friedmann, Michael R Marsman, Annelies W de Kater, et al.
Pageof 14